Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis.
This is a review of the pharmacology of strontium ranelate (Protelos, Protos, Protaxos, Bivalos, Osseor), and its efficacy and tolerability in the treatment of patients with postmenopausal osteoporosis. Strontium ranelate is a divalent strontium salt of ranelic acid that is capable of increasing bone formation and reducing bone resorption, thereby uncoupling and rebalancing bone turnover in favour of bone formation. The drug is effective in reducing the risk of fractures, including both vertebral and nonvertebral fractures, in patients with postmenopausal osteoporosis, according to data from two large, double-blind, placebo-controlled, multicentre trials of 5 years' duration, and reduced the risk of hip fracture in high-risk patients in a post hoc analysis of one trial. Moreover, data from patients who continued to receive the drug during the 3-year extension phases of these trials indicate that strontium ranelate continues to provide protection against new vertebral fractures and nonvertebral fractures for up to 8 years of therapy. It also improves bone mineral density at numerous sites and both increases markers of bone formation and decreases markers of bone resorption. Strontium ranelate is administered orally as a suspension and is generally well tolerated. The nature of adverse events was generally similar regardless of treatment duration in clinical trials, with the most commonly reported being nausea and diarrhoea over 5 years of treatment, and memory loss and diarrhoea during longer-term treatment. Although an increased risk of venous thromboembolism was associated with strontium ranelate relative to placebo over 5 years of treatment in a pooled analysis of clinical trials, postmarketing data have not confirmed this finding. Overall, the clinical data available suggest that strontium ranelate is an effective and generally well tolerated option for the first-line treatment of postmenopausal osteoporosis.
Deeks
Emma D
ED
Adis, Auckland, New Zealand. demail@adis.co.nz
Dhillon
Sohita
S
D000818:Animals; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D009942:Organometallic Compounds / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D013876:Thiophenes / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate
Bone. 1996 Jun;18(6):517-23
8805991
Bone. 2001 Aug;29(2):176-9
11502480
Osteoporos Int. 2010 Feb;21(2):339-49
19513577
Bone. 2008 Jun;42(6):1131-6
18378206
Osteoporos Int. 2010 Jan;21(1):157-65
19350339
Arthritis Rheum. 2008 Jun;58(6):1687-95
18512789
Bone. 2010 Feb;46(2):440-6
19716940
Rheumatology (Oxford). 2008 Jul;47 Suppl 4:iv17-19
18556645
J Bone Miner Res. 2006 Apr;21(4):536-42
16598373
Osteoporos Int. 2009 Aug;20(8):1417-28
19096745
Osteoporos Int. 2008 Apr;19(4):503-10
17929073
J Bone Miner Res. 2004 Dec;19(12):2012-20
15537445
Bone. 2009 Sep;45(3):460-5
19464401
Calcif Tissue Int. 2008 Nov;83(5):308-14
18843436
Curr Opin Rheumatol. 2009 Jul;21(4):356-62
19412103
Osteoporos Int. 2009 Apr;20(4):653-64
18763010
Osteoporos Int. 2010 Nov;21(11):1889-97
19957162
Osteoporos Int. 2006 Dec;17(12):1781-93
17009083
Osteoporos Int. 2008 Apr;19(4):399-428
18266020
N Engl J Med. 2004 Jan 29;350(5):459-68
14749454
J Bone Miner Res. 2007 Sep;22(9):1419-25
17547534
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004523
18254053
Br J Pharmacol. 2009 Aug;157(7):1291-300
19563530
Treat Endocrinol. 2006;5(6):347-58
17107220
J Clin Endocrinol Metab. 2007 Aug;92(8):3076-81
17566094
Bone. 2009 Dec;45(6):1059-64
19679207
Osteoporos Int. 2010 Feb;21(2):233-41
19436941
Bone. 2009 May;44(5):744-51
19130909
J Bone Miner Res. 2010 Mar;25(3):455-62
20201000
Menopause. 2009 Mar-Apr;16(2):413-21
19092711
Biochem Biophys Res Commun. 2007 Apr 6;355(2):307-11
17300752
Drugs Today (Barc). 2003 Feb;39(2):89-101
12698204
J Bone Miner Res. 2008 Mar;23(3):433-8
17997711
J Bone Miner Res. 2006 Jul;21(7):1113-20
16813532
Br J Clin Pharmacol. 2008 Nov;66(5):689-94
18754840
Calcif Tissue Int. 2010 Jan;86(1):82-9
19960189
Osteoporos Int. 2009 Jul;20(7):1101-6
19266136
Rheumatol Int. 2010 May;30(7):863-9
20035331
Arthritis Rheum. 2001 Nov;44(11):2611-9
11710717
Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):765-85
19028356
J Bone Miner Res. 2003 Jun;18(6):1082-7
12817762
Biochem Biophys Res Commun. 2004 Oct 29;323(4):1184-90
15451421
Clin Ther. 2005 Apr;27(4):361-76
15922811
Eur J Pharmacol. 2002 Aug 16;450(1):11-7
12176103
Metabolism. 2002 Jul;51(7):906-11
12077740
Curr Med Res Opin. 2007 Dec;23(12):3041-5
17967221
J Bone Miner Res. 1993 May;8(5):607-15
8511988
Osteoporos Int. 2005 Mar;16(3):239-54
15726235
Ann Rheum Dis. 2008 Dec;67(12):1736-8
18713788
Bone. 2003 Jul;33(1):115-23
12919706
Osteoporos Int. 2009 Oct;20(10):1663-73
19153678
J Clin Endocrinol Metab. 2005 May;90(5):2816-22
15728210
Ann Pharmacother. 2007 Jan;41(1):41-5
17179188
J Bone Miner Res. 2008 Feb;23(2):215-22
17922612
Bone. 2008 Jan;42(1):129-38
17945546
Clin Endocrinol (Oxf). 2009 Apr;70(4):522-6
18625000
Drugs Aging. 2008;25(11):963-86
18947264
Bone. 2007 Jan;40(1):218-22
17010685
J Biol Chem. 2009 Jan 2;284(1):575-584
18927086
J Clin Endocrinol Metab. 2002 May;87(5):2060-6
11994341
Horm Metab Res. 2009 Jul;41(7):559-62
19204890
J Cell Mol Med. 2009 Aug;13(8B):2189-99
20141614
Osteoporos Int. 2010 Apr;21(4):667-77
19597910
Ann Rheum Dis. 2008 Mar;67(3):335-9
17965119
Calcif Tissue Int. 2001 Sep;69(3):121-9
11683526
J Clin Invest. 2005 Dec;115(12):3318-25
16322775
Ann Pharmacother. 2006 Jun;40(6):1143-50
16735667
Curr Med Res Opin. 2009 Oct;25(10):2373-87
19650751
Osteoporos Int. 2010 May;21(5):723-32
19921087
J Bone Miner Res. 2009 Aug;24(8):1358-68
19338452
Curr Opin Rheumatol. 2006 Jun;18 Suppl 1:S11-5
16735840
Biochem Pharmacol. 2007 Aug 1;74(3):438-47
17531955
Br Med Bull. 2008;86:129-43
18477578
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326
16856092
Osteoporos Int. 2010 Jun;21(6):1031-6
19813043
Curr Med Res Opin. 2007 Feb;23(2):293-9
17288683
J Bone Miner Res. 2005 Sep;20(9):1569-78
16059629
Bone. 2009 Aug;45(2):200-6
19376283
Drugs Aging. 2007;24(1):37-55
17233546
Osteoporos Int. 2010 Dec;21(12):1993-2002
20082066
Bone. 2010 Apr;46(4):1038-42
20026265
Osteoporos Int. 2010 Jul;21(7):1181-7
19806285